Details:
Under the terms of the agreement, Takeda has exclusive rights to utilize Genevant’s LNP technology in the development and commercialization of specified nonviral gene therapies for up to two undisclosed rare liver diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: Undisclosed Upfront Cash: $303.0 million
Deal Type: Collaboration August 23, 2021